| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $3.0M | — |
| R&D Expense | $155.3M | +5.0% |
| SG&A Expense | $50.2M | +15.6% |
| Operating Income | -$202.5M | +1.1% |
| Income Tax | $0 | +100.0% |
| Net Income | -$195.9M | +1.1% |
| EPS (Basic) | -$1.65 | +24.3% |
| EPS (Diluted) | -$1.65 | +24.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $182.5M | +338.9% |
| Current Assets | $211.9M | +48.2% |
| Total Assets | $297.5M | +53.5% |
| Current Liabilities | $38.0M | -32.7% |
| Total Liabilities | $144.4M | +137.5% |
| Stockholders' Equity | $153.1M | +15.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$122.9M | +25.7% |
| Capital Expenditures | $7.3M | -16.4% |
| Investing Cash Flow | $68.5M | +265.9% |
| Financing Cash Flow | $195.9M | — |
| Free Cash Flow | -$130.2M | +25.3% |